{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "GBp", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.265, "exchange": "LSE", "shortName": "NUFORMIX PLC ORD 0.1P", "longName": "Nuformix plc", "messageBoardId": "finmb_126832716", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "marketState": "POSTPOST", "esgPopulated": false, "sharesOutstanding": 744308992, "bookValue": 0.006, "fiftyDayAverage": 0.30044, "fiftyDayAverageChange": -0.035440028, "fiftyDayAverageChangePercent": -0.11796041, "twoHundredDayAverage": 0.369705, "twoHundredDayAverageChange": -0.104705006, "twoHundredDayAverageChangePercent": -0.2832123, "marketCap": 1972418, "priceToBook": 44.166664, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1450339200000, "priceHint": 4, "regularMarketChange": 0.0, "regularMarketTime": 1683904747, "regularMarketDayHigh": 0.29, "regularMarketDayRange": "0.242 - 0.29", "regularMarketDayLow": 0.242, "regularMarketVolume": 1010185, "regularMarketPreviousClose": 0.265, "bid": 0.2, "ask": 0.29, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "GBP", "regularMarketOpen": 0.2574, "averageDailyVolume3Month": 4225880, "averageDailyVolume10Day": 4054635, "fiftyTwoWeekLowChange": 0.054999992, "fiftyTwoWeekLowChangePercent": 0.26190475, "fiftyTwoWeekRange": "0.21 - 0.95", "fiftyTwoWeekHighChange": -0.685, "fiftyTwoWeekHighChangePercent": -0.72105265, "fiftyTwoWeekLow": 0.21, "fiftyTwoWeekHigh": 0.95, "earningsTimestamp": 1688122740, "earningsTimestampStart": 1688122740, "earningsTimestampEnd": 1688122740, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.0, "symbol": "NFX.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "60 Gracechurch Street", "address2": "6th Floor", "city": "London", "zip": "EC3V 0HR", "country": "United Kingdom", "phone": "44 1223 627222", "website": "https://www.nuformix.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Dr. Joanne M. Holland", "age": 47, "title": "Consultant", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 66000, "fmt": "66k", "longFmt": "66,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Daniel John Gooding", "age": 48, "title": "Exec. Director", "yearBorn": 1974, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Benjamin  Harber", "title": "Company Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}